Institutional & Insider Ownership
5.7% of Interpace Biosciences shares are owned by institutional investors. 55.7% of Ethema Health shares are owned by insiders. Comparatively, 0.9% of Interpace Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Ethema Health has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.
Valuation & Earnings
This table compares Ethema Health and Interpace Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ethema Health | $18.76 million | 0.00 | -$2.18 million | N/A | N/A |
| Interpace Biosciences | $38.73 million | 0.18 | $24.58 million | ($0.05) | -32.20 |
Interpace Biosciences has higher revenue and earnings than Ethema Health.
Profitability
This table compares Ethema Health and Interpace Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ethema Health | -11.61% | N/A | -7.48% |
| Interpace Biosciences | 65.25% | 219.07% | 105.05% |
Summary
Interpace Biosciences beats Ethema Health on 6 of the 8 factors compared between the two stocks.
About Ethema Health
Ethema Health Corporation operates behavioral healthcare space specifically in the treatment of substance use disorders. It offers rehabilitation services. The company was formerly known as GreeneStone Healthcare Corporation and changed its name to Ethema Health Corporation in April 2017. Ethema Health Corporation is based in West Palm Beach, Florida.
About Interpace Biosciences
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for Ethema Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ethema Health and related companies with MarketBeat.com's FREE daily email newsletter.
